Risdiplam Therapy
Risdiplam Therapy is a pharmacotherapeutic approach that belongs to the class of survival motor neuron-2 (SMN2) splicing modulators, distinguished by its administration of the small molecule risdiplam to enhance full-length SMN protein production in patients with spinal muscular atrophy.
42
Publications
2.7K
Citations
577
Authors
168
Institutions
Publications per year
2017–2026
42
42
Hasane Ratni, Martin Ebeling, John D. Baird et al. · Journal of Medicinal Chemistry · 2018 · 520 citations · Full text
Medicine, Neurology, Pharmacology +14
Risdiplam in Type 1 Spinal Muscular Atrophy
Giovanni Baranello, Basil T. Darras, Nicolas Deconinck et al. · New England Journal of Medicine · 2021 · 419 citations · Full text
Medicine, Neurology, Neuroscience +13
1–5 of 42
577
13
h-index
12
h-index
12
h-index
Fondazione IRCCS Istituto Neurologico Carlo Besta, Italy
12 publications · 1.1K citations
11
h-index
11
h-index
1–5 of 577
168
Roche (Switzerland)
Basel, Switzerland
18 h-index
152 publications
19.5K citations
Roche (United Kingdom)
Welwyn Garden City, United Kingdom
12 h-index
23 publications
1.9K citations
University College London
London, United Kingdom
11 h-index
47 publications
12.5K citations
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
10 h-index
18 publications
2.1K citations
Centro Clinico Nemo
Milan, Italy
10 h-index
19 publications
1.3K citations

Great Ormond Street Hospital
London, United Kingdom
9 h-index
28 publications
7.6K citations
Stanford University
Stanford, United States
8 h-index
9 publications
867 citations
Hôpital Armand-Trousseau
Paris, France
7 h-index
8 publications
1.1K citations
1–8 of 168
5 publications · 96 citations
5
h-index
4 publications · 129 citations
4
h-index
ACTN · 2 publications · 74 citations
2
h-index
2 publications · 120 citations
2
h-index
2 publications · 71 citations
2
h-index
1–5